Why Prior Authorization Is Turning Into a Software Business

TL;DR: The recent wave of prior-authorization reform in U.S. health insurance looks generous on the surface. It is really a business-model upgrade. The control point is moving from blunt denials and phone trees into software, data standards, and faster machine-readable approvals, which means the winners may be the insurers and vendors that can make utilization management feel invisible while keeping the spending lever intact.

##The Old Fight Was About Paperwork. The New Fight Is About Workflow Ownership.

Picture a specialist office trying to schedule an outpatient scan. The old prior-authorization battle was a nurse, a portal, a fax, a callback, and a half-day lost to clerical drag.

Now picture the insurer side of that same transaction. CMS said on May 13 that 29 healthcare organizations joined its electronic prior authorization acceleration effort ahead of the January 1, 2027 deadline, while major payers including Aetna, Cigna, Elevance, Humana, and UnitedHealthcare are already in the mix.

That matters because the business is changing shape. Prior authorization is no longer just a political headache or a physician relations problem. It is becoming a workflow product.

The headline examples make that clear. UnitedHealthcare said on May 5 it will eliminate prior approval requirements for 30% of healthcare services that still need them, said prior auth applies to only 2% of its medical services, and said roughly 92% of submitted authorizations are approved in less than 24 hours on average. Aetna said on April 24 it has standardized 88% of its prior-auth volume, processes 83% in real time, and has eliminated more than 1 million provider calls through automation.

That is not a retreat from control. It is control getting better software.

##Fewer Authorizations Does Not Mean Less Management

The easy read is that insurers are finally backing down. The better read is that they are removing the cheapest-to-approve cases so they can spend less administrative labor on obvious yeses and reserve friction for the categories that still move cost.

AHIP and the Blue Cross Blue Shield Association said in April that participating plans have already eliminated 11% of prior authorizations, or about 6.5 million requests, including a reduction of more than 15% in Medicare Advantage. That sounds like a concession.

But it is also classic process triage. If a service has stable clinical guidelines and predictable utilization, the insurer does not need expensive manual review. It needs a cleaner rules engine, a standardized submission format, and better data flowing in from provider systems.

That is why this story belongs in business coverage, not just healthcare policy coverage.

The payer that can shift routine approvals into real-time pipes gets three things at once:

Lower admin cost per decision.
Better provider relations without giving up the utilization lever.
Cleaner data on where it still wants to say no, slow-walk, or ask harder questions.

In other words, prior authorization is being unbundled. The nuisance part is being automated away. The economic part is being preserved.

##The Real Market Is The Software Layer Between Doctor Intent And Insurer Payment

CMS is pushing the system there on purpose. Its April 10 proposed rule on drug prior authorization would extend electronic prior-authorization requirements to drugs, require faster decision windows, and force more public reporting on denials and appeals outcomes.

That means the monetizable asset is no longer just a coverage policy manual. It is the operating layer that translates physician requests, coding logic, clinical evidence, plan design, and audit visibility into a faster approval decision.

That creates a different set of commercial winners:

Insurers that can industrialize approvals without visibly inflaming members or providers.
EHR and revenue-cycle vendors that become the default pipes into payer rules.
Specialty benefit managers and workflow vendors that sit at the handoff point between prescription, procedure, and payment.

This is why Aetna’s decision to combine medical and pharmacy reviews into condition-specific bundles is more interesting than the press-release phrasing. It hints that the future product is not “fewer prior auths.” The future product is a more integrated permission system.

##The Trust Problem Is Still The Catch

If this were purely a software cleanup story, doctors would be celebrating already. They are not.

The AMA said on May 13 that only 33% of physicians believe the latest insurer pledge will make a meaningful difference. It also said 95% report delays to necessary care, 79% report patients abandoning treatment because of authorization challenges, and 26% report prior authorization has led to a serious adverse event.

That skepticism matters for investors because it shows the next bottleneck is not just policy design. It is credibility.

An insurer can remove a few million approvals and still lose the room if providers think the hard cases remain opaque, the peer reviewer is unqualified, or the automated system simply denies faster. Software can reduce labor. It does not automatically create trust.

So the real commercial question is not whether prior authorization gets smaller.

It is whether health plans can turn prior authorization into a low-friction infrastructure layer before regulators, employers, and providers decide the current version is too costly to defend.

That is a very different valuation story from “insurers are being nicer.”

##FAQ

#Why is this a finance story?

Because prior authorization affects medical-cost control, administrative expense, provider abrasion, regulatory exposure, and the software budget around payment workflows. That is margin architecture, not just patient messaging.

#Are insurers actually giving up a cost-control tool?

Not really. The evidence so far suggests they are automating easy approvals, standardizing submissions, and preserving tighter review where spending impact is larger or clinical judgment is less straightforward.

#What should investors watch next?

Watch which payers can show faster approvals and lower admin friction without losing medical-cost discipline. Also watch the vendors sitting between EHR workflows and payer decisions. That is where a lot of the hidden value may accumulate.